Robin Carr, Myricx Bio CEO

In piv­ot to buzzy AD­Cs, Lon­don biotech Myricx rais­es $114M with Lil­ly's sup­port

On the verge of rais­ing its Se­ries A in late 2021, Myricx Bio faced a tough choice.

The tox­i­c­i­ty pro­file for its IV and oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.